Effect of Genotype and Previous GH Treatment on Adiposity in Adults With Prader-Willi Syndrome

J Clin Endocrinol Metab. 2016 Dec;101(12):4895-4903. doi: 10.1210/jc.2016-2163. Epub 2016 Sep 23.

Abstract

Context: Adults with Prader-Willi syndrome (PWS) have an increased proportion of sc fat mass compared with body mass index (BMI)-matched controls, but whether the genotype influences body composition and metabolic profile remains controversial.

Objective: To assess body composition and metabolic features in adults with PWS, according to genetic subtype. In addition, the effect of previous GH treatment was assessed. Main Outcomes and Measures: Body composition (Dual Energy X-ray Absorptiometry) and metabolic parameters were compared in PWS adults (mean age, 25.5 ± 8.9 y) with deletion (n = 47) or uniparental disomy (UPD) (n = 26), taking into account GH treatment in childhood and/or adolescence. In subgroups, adipocyte size, fasting total ghrelin levels, and resting energy expenditure were measured, and hyperphagia was assessed by the Dykens Hyperphagia Questionnaire.

Main outcomes and measures: Body composition (Dual Energy X-ray Absorptiometry) and metabolic parameters were compared in PWS adults (mean age, 25.5 ± 8.9 y) with deletion (n = 47) or uniparental disomy (UPD) (n = 26), taking into account GH treatment in childhood and/or adolescence. In subgroups, adipocyte size, fasting total ghrelin levels, and resting energy expenditure were measured, and hyperphagia was assessed by the Dykens Hyperphagia Questionnaire.

Results: In the whole sample, the deletion group had a higher BMI compared with UPD (40.9 ± 11.5 vs 34.6 ± 9.6 kg/m2, P = .02), but there was no difference between groups in percent body fat, metabolic profile, adipocyte size, resting energy expenditure, hyperphagia score, or ghrelin levels. In subjects previously treated with GH, BMI was not different between UPD and deletion groups (33.0 ± 9.7 vs 33.5 ± 11.1 kg/m2). In addition, previous GH treatment was associated with decreased percent body fat and adipocyte volume only in the deletion group.

Conclusion: A deletion genotype in adults with PWS is associated with increased BMI. GH treatment in childhood and/or adolescence limits this deleterious phenotypic effect with improved adiposity markers. This study suggests relationships between the molecular phenotype of PWS and adipose tissue development as well as sensitivity to GH.

Publication types

  • Comparative Study

MeSH terms

  • Absorptiometry, Photon
  • Adipocytes*
  • Adiposity*
  • Adolescent
  • Adult
  • Body Mass Index*
  • Chromosome Deletion
  • Chromosomes, Human, Pair 15
  • Cohort Studies
  • Female
  • Genotype
  • Growth Hormone / therapeutic use*
  • Humans
  • Male
  • Middle Aged
  • Phenotype
  • Prader-Willi Syndrome / classification
  • Prader-Willi Syndrome / genetics*
  • Prader-Willi Syndrome / metabolism*
  • Uniparental Disomy
  • Young Adult

Substances

  • Growth Hormone

Supplementary concepts

  • Chromosome 15q, partial deletion